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Objective: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with
pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid
spending on various methods of contraception and on pregnancy care including unintended pregnancies.
Methods: We analyzed Medicaid health claims data from 2004 to 2010. Women 14–49 years of age initiating
contraceptive methods and pregnant women were included as separate cohorts. Medicaid spending was
summarized using mean all-cause and contraceptive healthcare payments per patient per month (PPPM) over a
follow-up period of up to 12 months. Medicaid payments were also estimated in 2008 per female member of
childbearing age per month (PFCPM) and per member per month (PMPM). Medicaid payments on unintended
pregnancies were also evaluated PFCPM and PMPM in 2008.
Results: For short-acting reversible contraception (SARC) users, all-cause payments and contraceptive payments
PPPM were respectively $365 and $18.3 for oral contraceptive (OC) users, $308 and $19.9 for transdermal users,
$215 and $21.6 for vaginal ring users, and $410 and $8.8 for injectable users. For long-acting reversible contracep-
tion (LARC) users (follow-up of 9–10 months), corresponding payments were $194 and $36.8 for IUD users, and
$237 and $29.9 for implant users. Pregnancy cohort all-cause mean healthcare payments PPPM were $610. Pay-
ments PFCPM and PMPM for contraceptives were $1.44 and $0.54, while corresponding costs of pregnancies were
estimated at $39.91 and $14.81, respectively. Payments PFCPM and PMPM for contraceptives represented a small
fraction at 6.56% ($1.44/$21.95) and 6.63% ($0.54/$8.15), respectively of the estimated payments for unintended
pregnancy.
Conclusions: This study of a large sample of Medicaid beneficiaries demonstrated that, over a follow-up period of
12 months, Medicaid payments for pregnancy were considerably higher than payments for either SARC or LARC
users. Healthcare payments for contraceptives represented a small proportion of payments for unintended
pregnancy when considering the overall Medicaid population perspective in 2008.
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Healthcare costs associated with pregnancy and delivery,
and with the care of newborn infants are significant; they
represent the two most expensive conditions requiring
hospitalization billed to Medicaid in the US [1]. For sev-
eral decades, low-income women who would not other-
wise have been eligible for Medicaid were covered for* Correspondence: flaliberte@analysisgroup.com
1Groupe d’analyse, Ltée, 1000 rue de la Gauchetière Ouest Bureau 1200,
H3B 4 W5 Montréal, Québec, Canada
Full list of author information is available at the end of the article
© 2014 Laliberté et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe care of pregnancy and the post-partum period [2].
As a result, public insurance programs, primarily Medic-
aid, pay for around half of all births in the United States
(US) and for two thirds of all births resulting from unin-
tended pregnancies [3,4], Unintended pregnancies repre-
sent approximately 50% of all pregnancies in the US
(more than 3 million each year) and are five times more
frequent in poor women than affluent women [5]. These
unintended pregnancies result in the majority of the 1.2
million abortions per year [6] and are associated with in-
creased risk of detrimental prenatal parental behaviorl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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those carried to term; [7-10] they can also impact
women’s health and prospects for education and impose
considerable financial burden on families and society
[11-13].
The Institute of Medicine and the US Department of
Health and Human Services identify contraception as an
essential component of preventive health care. Studies
on cost of contraceptive coverage relative to pregnancy
and maternity care have consistently reported cost sav-
ings associated with contraceptive coverage [14-16] Ad-
equate coverage and access to contraception are thus
important issues for payers and employers to consider if
they support the public health goal of reducing unin-
tended pregnancies and their costs.
Not all types of contraception methods, however, are
equally effective at preventing unintended pregnancies
[17]. In particular, among contraceptive users, discon-
tinuation and imperfect use of oral contraceptives (OCs)
is a leading cause of unintended pregnancy [18,19]. In
the recent Contraceptive CHOICE Project, a research
study that supports the efficacy of long-acting reversible
contraceptive (LARC) methods as a means of reducing
unintended pregnancies, participants using oral contra-
ceptive pills, a transdermal patch, or a vaginal ring had
an adjusted risk of contraceptive failure that was 20
times as high as the risk among those using LARC [20].
The unadjusted failure rate among participants who
used pills, patch, or ring was 4.55 per 100 participant-
years, as compared with 0.27 for those who used LARC.
The Contraceptive CHOICE Project also reported that
when provided with counseling and their choice of
contraceptive method at no cost, 67% of eligible women
chose an intrauterine device (IUD) or an implant, com-
pared with less than 6% of women in the general popula-
tion who chose these methods [21].
The Affordable Care Act (ACA) aims to expand Me-
dicaid coverage to millions of low-income Americans.
The ACA Medicaid expansion may be costly for some
states [22], but it could also lead to potential cost-offsets
since Medicaid includes contraceptive coverage which
should result in fewer unintended pregnancies. This
retrospective study of health insurance claims used
multi-state Medicaid data to evaluate all-cause health-
care payments for women using different types of
contraception and for pregnant women. The relative
spending on contraceptive methods was also compared.
Moreover, payments on contraception and on pregnancy
care among all Medicaid beneficiaries were assessed, as
well as the estimated payments on unintended pregnan-
cies. We hypothesized that the costs of contraceptive
coverage to a health plan are considerably lower than
payments for unintended pregnancy care and that LARC
methods provide maximum cost savings.Methods
Data source
We analyzed the combined Medicaid health claims data
from 2004 to 2010 for five states (Florida, Iowa, Kansas,
Missouri, and New Jersey) for whom we had access to their
Medicaid data. The Medicaid database used contains
complete medical and pharmaceutical claims for over 11
million Medicaid beneficiaries including Medicare/Medic-
aid dual eligible beneficiaries. As showed in Table 1, the
demographic characteristics (e.g., age groups, race) of
women Medicaid beneficiaries from the combined studied
states were representatives of the demographic of all
women Medicaid beneficiaries in the US as evaluated in
2008. The database includes information on enrollee eligi-
bility, physician visits, hospitalizations, long term care ser-
vices, and prescription drugs. Of note, in addition to
standard demographic variables such as age and gender, the
database includes variables such as aid category (blind/dis-
abled, Medicare eligible) and race. The medical claims also
contain diagnosis and procedure information, and the pre-
scription drug claims contain information on the name,
dosage, formulation, and days of supply of the medication
as well as the amount of the Medicaid payment for each
claim.
Medicaid database are de-identified and fully compli-
ant with all Health Insurance Portability and Account-
ability Act of 1996 privacy and security requirements to
protect participant anonymity and confidentiality. Insti-
tutional review board (IRB) approval and informed con-
sent were not required for this study.
Study design
The first set of analyses (Retrospective Cohort Design)
focused on payments made on behalf of Medicaid-
covered women of reproductive age who were either ini-
tiating contraceptives – whether short-acting reversible
(SARC: OC, transdermal, vaginal, or injectable) or LARC
(intrauterine device [IUD] or implant) – or became
pregnant during the study period. In addition the ana-
lyses set out to compare spending on different types of
contraceptives compared to oral contraceptives. A sec-
ond set of analyses (Actuarial Analysis) examined these
payments in relation to all Medicaid enrollees included
in the study regardless of gender and utilization of ser-
vices. Of note, the SARC and the LARC contraceptive
methods were studied individually (OC, IUD, etc.).
Retrospective cohort design
A retrospective cohort design was used to evaluate contra-
ception and pregnancy healthcare payments for Medicaid-
covered women of reproductive age during up to
12-months of follow-up. An observation period of only up
to 12 months was chosen to take into account the high dis-
continuation rate among SARC users [18,19] and the fact
Table 1 Descriptive statistics on women medicaid beneficiaries in the studied States (NJ, FL, MO, KS, and IA) compared
to medicaid beneficiaries in the US in 2008
Beneficiaries characteristics Medicaid beneficiaries from the combined studied states
(NJ, FL, MO, KS, and IA) in 2008
Medicaid beneficiaries in the US in 20081
Women beneficiaries (%) 58.4% 59.0%
Age of women beneficiaries (%)
< 15 years 37.4% 34.3%
15-18 years 7.5% 7.8%
19-44 years 30.5% 35.8%
45 or more years 24.6% 22.2%






1. Obtained from the Medicaid Statistical Information System (MSIS) State Summary Datamart. Available at http://www.cms.gov/Research-Statistics-Data-and-
Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/MSIS-Mart-Home.html. Accessed January 10, 2014.
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continued later because they wanted to get pregnant. A
follow-up of 12 months was also appropriate to evaluate
pregnancy healthcare payments.
Women 14–49 years of age enrolled for ≥6 months
prior to initiating SARC or LARC contraceptive methods
and pregnant women were included as separate cohorts.
Each woman was followed from the first contraceptive
claim (contraceptive cohort) or from the first pregnancy
or pregnancy-related diagnosis (pregnancy cohort) claim,
until the earliest of 12 months of follow-up, health plan
disenrollment, or end of data availability. Of note, since
we studied real-world contraceptive use and pregnancy
occurrences, the contraceptive-users cohorts could in-
clude women who became pregnant (either because they
wanted to become pregnant or because they had an un-
intended pregnancy). It is also possible that a patient ini-
tiated a contraceptive and then became pregnant, in
which case that patient would be in both a contraceptive
cohort and in the pregnancy cohort. Similarly, by study-
ing real-world usage, women were allowed to switch
contraceptive methods during the up to 12 months of
follow-up.
Medicaid spending for each cohort of contraceptive
users up to 12 months after the index date was sum-
marized using mean all-cause healthcare payments and
contraceptive payments. All-cause, pregnancy-related, and
pregnancy-related complication payments were calculated
for the pregnancy cohort. Pregnancy-related payments were
identified as hospitalizations and outpatient claims with a
primary or a secondary diagnosis for normal pregnancy
(ICD-9-CM: V22), supervision of high-risk pregnancy
(ICD-9-CM: V23), outcome of delivery (ICD-9-CM: V27),
normal delivery (ICD-9-CM: 650.x), and complications ofpregnancy, childbirth, and the puerperium (ICD-9-CM:
630.×-676.×). Pregnancy-related complications payments,
a subset of pregnancy related payments, included complica-
tions of pregnancy, childbirth, and the puerperium.
Neonatal care payments were not included in pregnancy-
related payments since the focus of this study was on the
costs of the pregnancy. Adding neonatal care in pregnancy-
related payments would considerably increase pregnancy-
related costs, which makes our estimated cost of pregnancy
conservative.
Actuarial analysis
Since women can be expected to be on contraception
for many years, while women who become pregnant be-
come so at a fairly low rate during the same time frame
with a limited number of pregnancies being carried to
term, an actuarial analysis was also conducted that has
the advantage of evaluating contraception and pregnancy
healthcare Medicaid payments for both new and on-
going contraceptive users, as well as newly pregnant or
ongoing pregnant women.
The study population for this analysis included all Me-
dicaid members (i.e., all females regardless of contracep-
tive use and pregnancy status and all males) with at least
one month of Medicaid coverage in 2008. No other in-
clusion or exclusion criteria were applied. Each member
was followed from the first day of eligibility in 2008 until
the earliest of December 31, 2008, or health plan disen-
rollment. For example, if a member was enrolled in Me-
dicaid before 2008 and was eligible until the end of
March 2008, this patient was studied from January 1,
2008, through March 31, 2008. A member enrolled July
1, 2008 and still eligible at the end of 2008 was studied
from July 1, 2008, through December 30, 2008. The
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also studied.
Statistical analysis
For the 6-month period preceding the index date, patient
baseline characteristics were described with means and
standard deviations for continuous variables and with fre-
quencies and percentages for categorical variables.
For the retrospective cohort analysis, Medicaid spend-
ing for each cohort was summarized using mean health-
care payments per patient per month (PPPM). The
PPPM is the aggregated payment divided by aggregated
months of the follow-up period, with both values
summed across all patients, an approach commonly used
in non-experimental study settings to account for differ-
ent lengths of observation periods among study patients.
The PPPM cost is a useful measure to evaluate the costs
among a group of patients since it evaluates the mean
cost per month among these individuals.
To evaluate all-cause costs and contraceptive costs of OC
users compared to other contraceptive users, ordinary least
square regressions were used in both univariate and multi-
variate analyses to evaluate unadjusted and adjusted
payment differences. Confidence intervals (95% CI) were
calculated using a nonparametric bootstrap to account for
the non-normal distribution of data. Covariates included
for adjustments in the multivariate analysis were age, re-
gion, race, year of index date, Charlson comorbidity index,
other comorbidities (cardiovascular diseases, hypertension,
diabetes, pelvic inflammatory disease, alcohol, smoking),
parous status, and baseline healthcare payments. The
Charlson comorbidity index is a measure of the sickness of
patients that is commonly used in claims analyses. Each of
the 17 conditions (e.g., congestive heart failure, renal dis-
ease, cancer) in the Charlson comorbidity index is assigned
a score and the total score of each patient was evaluated
and calculated during the 6-month baseline period [23].
Baseline healthcare payments represented the total Medic-
aid payments for patients during the 6-month baseline
period prior to the index date.
For the actuarial analysis, Medicaid payments for all
contraceptives, OC, IUD, and pregnancy care in 2008
per female member of childbearing age per month
(PFCPM) and per member per month (PMPM) were
evaluated. These metrics are different from the PPPM
method described above since they evaluated the costs
not just among women in the contraceptive or the preg-
nancy cohorts, but in a larger group of women regard-
less of their contraceptive usage in the case of the
PFCPM analysis and in an even larger group that in-
cluded all Medicaid members (female or male) for the
PMPM analysis. PFCPM payments were calculated as
the total payments for women aged 14 to 49 divided
by patient-months of observation. Similarly, PMPMpayments were calculated as PFCPM payments but di-
vided by all Medicaid beneficiaries, thus giving a per-
spective of the same payments, but on all Medicaid
beneficiaries instead of just female members of child-
bearing age. An individual could thus be enrolled for
only part of the year. Retrospective actuarial analyses
using similar patient-year calculations have also been
conducted in previous studies [24,25].
In addition, Medicaid payments for unintended preg-
nancy were also estimated based on rates of unintended
pregnancies reported in the literature for Florida (59%),
Iowa (44%), Kansas (48%), New Jersey (55%), and Mis-
souri (53%) [26]. By applying these proportions to corre-
sponding pregnant women included in the current
study, we obtained a combined unintended pregnancy
rate of 55%.
All payments were inflation-adjusted to 2011 U.S. dol-




Figure 1 summarizes the study cohort selection. SARC
users (OC: 115,873; transdermal: 11,577; vaginal ring:
7,970; injectable: 29,817) and LARC users (IUD: 37,767;
implant; 6,526) were identified. For the pregnancy co-
hort, a total of 97,972 pregnant women were identified.
Table 2 presents the baseline characteristics of the
contraceptive and pregnancy cohorts.
Mean age was 22.7 years for OC users, 22.3 years for
transdermal users, 24.0 years for vaginal ring users,
22.6 years for injectable users, 24.9 years for IUD users,
and 21.7 years for implant users, while the mean age for
the pregnancy cohort was 23 years. It has been estimated
that around 50% of women under 25 years rely on OC
for contraception in the US, while the corresponding
proportion for women aged 40–44 is only around 10%
of women [27]. The mean age of 22.7 years we found for
the OC group is thus in a range that is representative of
what we would expect for OC users in the US. IUDs and
implants have been found to be used mostly by women
aged 25–39, married and cohabiting women, women
covered by Medicaid, and women with no religious affili-
ation [28]. Since women covered by Medicaid have been
identified as a group likely to use IUDs and implants, it
might explain the relatively young age of 24.9 and
21.7 years for IUD and implants users, respectively, that
we found in the current study. The mean age for the
birth of the first child in the US has been estimated at
25 years old [29], while the mean age of women in the
pregnancy cohort in our study was lower at 23.3 years.
In general, IUDs tend to be used by parous women [30].
In the current study we found a qualitatively higher propor-
tion of women who had a parous status at baseline among
Figure 1 Patients’ disposition flow chart for retrospective cohort analysis.
Laliberté et al. Reproductive Health 2014, 11:20 Page 5 of 11
http://www.reproductive-health-journal.com/content/11/1/20IUD users (84.2%) compared to implant (64.4%), OC
(43.4%), transdermal (43.8%), vaginal ring (57.0%), and in-
jectable methods (46.0%).
The mean follow-ups were 317 days for OC users,
324 days for transdermal users, 316 days for vaginal ring
users, 325 days for injectable users, 265 days for IUD
users, and 305 days for implant users days, respectively
(11 months for SARC users and 9–10 months for LARC
users).
Switch from the index contraceptive
Within 12 months of the index date, the proportion of
SARC users switching from index medication to another
type of contraceptive was 5.2% for OC users, 18.1% for
transdermal users, 10.4% for vaginal ring users, and 9.9%
for injectable users. The corresponding proportion of
LARC users switching from index medication to anothercontraceptive was 5.2% for IUD users and 9.1% for im-
plant users.
Healthcare payments associated with contraceptives and
pregnancy
All-cause healthcare payments and payments for contra-
ceptive users are presented in Table 3. Mean all-cause
and contraceptive payments PPPM were respectively
$365 and $18.3 for OC users, $308 and $19.9 for trans-
dermal users, $215 and $21.6 for vaginal ring users,
$410 and $8.8 for injectable users, $194 and $36.8 for
IUD users, and $237 and $29.9 for implant users.
Despite important variance in unadjusted all-cause
healthcare payments among contraceptive users, ad-
justed all-cause payments PPPM of vaginal ring, trans-
dermal, and injectable users were not significantly
different relative to OC users, with payment differences
Table 2 Demographics and clinical characteristics of the study cohorts
Index contraceptive















Age, years, mean (±SD) [Median] 22.7 (7.0) [21] 22.3 (6.4) [21] 24.0 (5.6) [23] 22.6 (7.2) [21] 24.9 (5.6) [24] 21.7 (5.1) [21] 23.3 (6.7) [21]
Age distribution, years, n (%)
14-16 yrs 22,626( 19.5%) 2,145 (18.5%) 378 (4.7%) 6,037 (20.2%) 491 (1.3%) 871 (13.3%) 10,158 (10.4%)
17-19 yrs 24,784 (21.4%) 2,555 (22.1%) 1,306 (16.4%) 6,332 (21.2%) 4,278 (11.3%) 1,575 (24.1%) 27,917 (28.5%)
20-24 yrs 30,136 (26.0%) 3,275 (28.3%) 3,110 (39.0%) 8,112 (27.2%) 16,480 (43.6%) 2,559 (39.2%) 24,194 (24.7%)
25-29 yrs 19,451 (16.8%) 2,039 (17.6%) 1,998 (25.1%) 4,627 (15.5%) 9,748 (25.8%) 1,047 (16.0%) 17,864 (18.2%)
30-34 yrs 10,162 (8.8%) 926 (8.0%) 765 (9.6%) 2,259 (7.6%) 4,028 (10.7%) 297 (4.6%) 10,205 (10.4%)
35-39 yrs 5,170 (4.5%) 409 (3.5%) 292 (3.7%) 1,342 (4.5%) 1,856 (4.9%) 130 (2.0%) 5,335 (5.4%)
40-44 yrs 2,487 (2.1%) 171 (1.5%) 97 (1.2%) 744 (2.5%) 668 (1.8%) 36 (0.6%) 1,903 (1.9%)
45-49 yrs 1,057 (0.9%) 57 (0.5%) 24 (0.3%) 364 (1.2%) 218 (0.6%) 11 (0.2%) 396 (0.4%)
Region, n (%)
New Jersey 28,532 (24.6%) 3,754 (32.4%) 2,670 (33.5%) 3,976 (13.3%) 3,414 (9.0%) 196 (3.0%) 31,391 (32.0%)
Florida 21,518 (18.6%) 2,142 (18.5%) 1,507 (18.9%) 3,102 (10.4%) 11,067 (29.3%) 590 (9.0%) 16,138 (16.5%)
Missouri 40,641 (35.1%) 3,239 (28.0%) 2,347 (29.4%) 7,381 (24.8%) 12,923 (34.2%) 2,912 (44.6%) 22,716 (23.2%)
Kansas 7,083 (6.1%) 571 (4.9%) 274 (3.4%) 3,022 (10.1%) 2,801 (7.4%) 328 (5.0%) 4,946 (5.0%)
Iowa 18,099 (15.6%) 1,871 (16.2%) 1,172 (14.7%) 12,336 (41.4%) 7,562 (20.0%) 2,500 (38.3%) 22,781 (23.3%)
Race, n (%)
White 72,948 (63.0%) 5,669 (49.0%) 4,186 (52.5%) 13,168 (44.2%) 22,335 (59.1%) 3,534 (54.2%) 46,802 (47.8%)
Black 22,065 (19.0%) 3,723 (32.2%) 2,263 (28.4%) 9,532 (32.0%) 5,914 (15.7%) 1,211 (18.6%) 30,324 (31.0%)
Latin/Hispanic 9,434 (8.1%) 1,077 (9.3%) 735 (9.2%) 1,430 (4.8%) 4,373 (11.6%) 289 (4.4%) 8,704 (8.9%)
Others/Unknown 11,426 (9.9%) 1,108 (9.6%) 786 (9.9%) 5,687 (19.1%) 5,145 (13.6%) 1,492 (22.9%) 12,142 (12.4%)
Year of index
date, n (%)
2005 17,725 (15.3%) 5,209 (45.0%) 702 (8.8%) 4,602 (15.4%) 2,724 (7.2%) 14 (0.2%) 14,641 (14.9%)
















Table 2 Demographics and clinical characteristics of the study cohorts (Continued)
2007 24,927 (21.5%) 1,529 (13.2%) 1,919 (24.1%) 6,158 (20.7%) 7,790 (20.6%) 696 (10.7%) 20,609 (21.0%)
2008 27,136 (23.4%) 1,393 (12.0%) 1,934 (24.3%) 6,532 (21.9%) 11,813 (31.3%) 2,186 (33.5%) 24,030 (24.5%)
2009 16,850 (14.5%) 890 (7.7%) 1,339 (16.8%) 4,750 (15.9%) 7,208 (19.1%) 2,287 (35.0%) 14,335 (14.6%)
2010 6,984 (6.0%) 355 (3.1%) 528 (6.6%) 1,798 (6.0%) 3,494 (9.3%) 1,311 (20.1%) 5,893 (6.0%)
Charlson comorbidity index1, n (%)
0 103,869 (89.6%) 10,576 (91.4%) 7,222 (90.6%) 26,381 (88.5%) 34,189 (90.5%) 6,031 (92.4%) 89,246 (91.1%)
1 10,013 (8.6%) 832 (7.2%) 656 (8.2%) 2,646 (8.9%) 3,070 (8.1%) 436 (6.7%) 7,054 (7.2%)
2 1,348(1.2%) 109 (0.9%) 60 (0.8%) 474 (1.6%) 363 (1.0%) 36 (0.6%) 972 (1.0%)
3 299 (0.3%) 17 (0.1%) 13 (0.2%) 118 (0.4%) 70 (0.2%) 12 (0.2%) 234 (0.2%)
4 72 (0.1%) 9 (0.1%) 0 (0.0%) 36 (0.1%) 21 (0.1%) 2 (0.0%) 66 (0.1%)
5 or more 272 (0.2%) 34 (0.3%) 19 (0.2%) 162 (0.5%) 54 (0.1%) 9 (0.1%) 400 (0.4%)
Other comorbidities1, n (%)
Cardiovascular diseases 2,737 (2.4%) 215 (1.9%) 179 (2.2%) 823 (2.8%) 1,135 (3.0%) 153 (2.3%) 1,607 (1.6%)
Hypertension 3,125 (2.7%) 202 (1.7%) 199 (2.5%) 974 (3.3%) 1,246 (3.3%) 134(2.1%) 2,182 (2.2%)
Diabetes 2,705 (2.3%) 192 (1.7%) 150 (1.9%) 697 (2.3%) 1,037 (2.7%) 97 (1.5%) 1,703 (1.7%)
Pelvic inflammatory disease 8,851 (7.6%) 945 (8.2%) 843 (10.6%) 2,511 (8.4%) 3,704 (9.8%) 475 (7.3%) 7,350 (7.5%)
Alcohol 697 (0.6%) 49 (0.4%) 42 (0.5%) 270 (0.9%) 161 (0.4%) 30 (0.5%) 753 (0.8%)
Smoking 5,630 (4.9%) 539 (4.7%) 546 (6.9%) 2,035 (6.8%) 3,206(8.5%) 549 (8.4%) 2,945(3.0%)
Parous status2, n (%) 50,312 (43.4%) 5,072 (43.8%) 4,541 (57.0%) 13,709 (46.0%) 31,802 (84.2%) 4,204 (64.4%) 2,998 (3.1%)
Baseline healthcare payments1, dollars, mean (±SD)
Inpatient services $1,615 (4,453) $1,411 (4,133) $1,634 (3,344) $1,554 (4,482) $2,648 (3,770) $1,774 (3,295) $169 (3,021)
Outpatient $1,574 (4,524) $1,413 (4,279) $1,106 (2,009) $1,856 (4,947) $1,539 (1,796) $1,469 (1,930) $872 (2,461)
Long-term care3 services $78 (2,919) $32 (1,810) $0 (6) $56 (1,881) $14 (1,142) $0 (18) $29 (1,697)
Emergency room services $37 (161) $36 (138) $30 (114) $49 (190) $34 (126) $46 (161) $40 (227)
Pharmacy $298 (1,554) $221 (924) $181 (919) $302 (1,409) $170 (750) $317 (927) $204 (1,031)
Total payments $3,602 (7,598) $3,113 (6,951) $2,951 (4,236) $3,818 (7,826) $4,405 (4,560) $3,606 (4,269) $1,315 (4,914)
Observation period4, days, mean (±SD) 317 (91) 324 (88) 316 (90) 325 (90) 265 (133) 305 (101) 337 (63)
Notes: SARC: short-acting reversible contraceptive; LARC: long-acting reversible contraceptive; OC: oral contraceptive; IUD: intrauterine device.
1. Based on a period of 180 days prior to index date.
2. Identified by claims with ICD-9-CM codes for delivery any time prior to the index date. The mother status, available in FL, was also used to identify parous status, as well as the family ID in NJ.
3. Identified with service claims for long-term care, skilled nursing facility, intermediate care facility, and swing beds.
















Table 3 All-cause and contraceptive healthcare payments per patient per month (PPPM) for contraceptive users1









Unadjusted Adjusted2 (95% CI) Unadjusted Adjusted2 (95% CI)
Index contraceptive
OC (N = 115,873) $365 Reference Reference $18.3 Reference Reference
Transdermal (N = 11,577) $308 -$57.1 -$4.4 (−17.5;8.6) $19.9 $1.7 $3.6 (3.1; 4.0)
Vaginal ring (N = 7,970) $215 -$150 $7.5 (−6.5;23.6) $21.6 $3.3 $5.1 (4.6; 5.6)
Injectable (N = 29,817) $410 $45.1 $8.2 (−2.1;18.3) $8.8 -$9.4 -$9.6 (−9.8; −9.4)
IUD (N = 37,767) $194 -$171 -$51.8 (−58.1;-45.0) $36.8 $18.6 $14.9 (14.5; 15.3)
Implant (N = 6,526) $237 -$128 -$52.5 (−64.2;-41.1) $29.9 $11.6 $7.4 (6.6; 8.1)
Notes: 1. From the index date until the earliest date between health plan disenrollement, lack of follow-up data, or 12 months after the index date.
2. Adjusted for age, region, race, year of index date, charlson comorbidity index, other comorbidities, parous status, and baseline healthcare payments.
3. Payments for any contraceptives (OC, IUD, transdermal, ring, injectable, and implant).
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respectively. In contrast, adjusted all-cause healthcare
payments PPPM for IUD and implant users were signifi-
cantly lower compared to OC users, with differences of
-$51.8 (−58.1;-45.0) and -$52.5 (−64.2;-41.1), respect-
ively. These lower all-cause payments for LARC users
were observed even if they had higher adjusted contra-
ceptive payments compared to OC users, with PPPM
differences of $14.9 (14.5;15.3) for IUD users and $7.4
(6.6;8.1) for implant users relative to OC users.
Table 4 reports healthcare payments for the pregnancy
cohort. All-cause mean healthcare payments PPPM of the
pregnancy cohort were $610, including $391 for claims dir-
ectly related to pregnancy, which represents 64% of all-
cause payments. Almost 90% of the total pregnancy and
pregnancy-related payments ($344 of $391) were attribut-
able to pregnancy-related complications.
Actuarial analysis
A total of 7,031,223 Medicaid members and 2,712,765
women of childbearing age were identified in 2008.
Among women aged 14 to 49 years, OC and IUD pay-
ments were made for 4.6% (123,955/2,712,765) and 1%
(28,399/2,712,765) of women, respectively, while 13.4%Table 4 Healthcare payments for the pregnancy cohort
(n = 97,972)1









1. From the index date until the earliest date between health plan
disenrollment, lack of follow-up data, or 12 months after the index date.(363,968/2,712,765) had payments for pregnancy-related
services (data not shown).
Payments PFCPM for all contraceptives, IUD, OC, and
pregnancy were $1.44, $0.39, $0.60, and $39.91, respect-
ively (Figure 2). Payments PFCPM for all contraceptives,
IUD, and OC thus represented a small fraction of the es-
timated payments for pregnancy at 3.61% ($1.44/$39.91),
0.98% ($0.39/$39.91), and 1.50% ($0.60/$39.91), respect-
ively. Similar proportions were found between contra-
ceptives and pregnancy payments when evaluated
PMPM at 3.65% ($0.54/$14.81), 1.01% ($0.15/$14.81),
and 1.55% ($0.23/$14.81) for all contraceptives, IUD,
and OC, respectively.
Payments for unintended pregnancy were estimated at
$21.95 PFCPM and at 37% of that amount ($8.15) when
evaluated PMPM. Payments PFCPM for all contracep-
tives, IUD, and OC also represented a small proportion
of the estimated payments for unintended pregnancy at
6.56% ($1.44/$21.95), 1.78% ($0.39/$21.95), and 2.73%
($0.60/$21.95), respectively. The corresponding propor-
tion PMPM for all contraceptives, IUD, and OC where
estimated at 6.63% ($0.54/$8.15), 1.84% ($0.15/$8.15),
and 2.82% ($0.23/$8.15), respectively.
Discussion
This large study of Medicaid beneficiaries reported the
spending on contraceptive users and pregnancy-related
healthcare payments and showed higher all-cause
healthcare payments for pregnant women compared to
contraceptive users. The study also showed that pay-
ments PFCPM and PMPM for contraceptives repre-
sented a small fraction of the estimated payments for
pregnancy; this finding was expected given that preg-
nancy and delivery are among the most expensive condi-
tions for insurers. Our study results suggest that
coverage of the costs of contraception lower overall ex-
pected costs for a health plan. Given that about two-
Figure 2 Payments PFCPM and PMPM for all contraceptives, IUD, OC, and pregnancy in 2008. Notes: PFCPM: per female member of
childbearing age per month; PMPM: per member per month; OC: oral contraceptive; IUD: intrauterine device a. Unintended pregnancies were
estimated at 55% based on an article by Finer and colleagues (Unintended Pregnancy Rates at the State Level, Perspectives on Sexual and
Reproductive Health 2011; 43:78-87).
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ing age [31], the high level of unintended pregnancies
[5], and the fact that Medicaid covers around two thirds
of these pregnancies [3,4], access to adequate contracep-
tive coverage fills a key public health care need.
Although the purpose of this research was not to study the
impact of the ACA, these findings are particularly relevant
given that the Medicaid expansions under the ACA will result
in much larger numbers of women being eligible for coverage
by Medicaid, at least in those states that choose to expand
their Medicaid programs [2]. These results are also of import-
ance for states that have not yet decided to enter the ACA as
they showed potential cost-offsets that could result in more
women being eligible for coverage by Medicaid (including
contraceptive coverage), especially given the high number of
unintended pregnancies among Medicaid beneficiaries [5].
Previous studies have reported savings for contraceptive
coverage use relative to pregnancy and maternity care
[14-16]. Family PACT, California’s publicly-funded family
planning program, estimated savings of more than $7.00
for every $1.00 spent on services and supplies for implant
and intrauterine contraceptives, while $1.00 spent for in-
jectable contraceptives translated to savings of $5.60; $4.07
for oral contraceptives; $2.99 for the patch; and $2.55 for
the vaginal ring [14]. A study by Frost and colleagues esti-
mated public expenditure savings for family planning care
of $4.02 for every dollar spent [15]. A study by Trussell
and colleagues concluded that the least expensive and most
cost-effective of the examined methods were the IUD and
vasectomy, and that any mode of contraception is less ex-
pensive than no method [16]. In the current study, we
found similar trends: all-cause healthcare payments PPPM
of pregnant women were higher compared to those of
women using contraceptives after up to one year of follow-
up (11 months for SARC users and 9–10 months for
LARC users). Furthermore, LARC users were associatedwith lower adjusted all-cause payments compared to OC
users despite higher contraceptive payments associated
with the initial dispensing and insertion of LARC. Of note,
PPPM contraceptive payments for LARC users are related
to the chosen follow-up period since these payments all oc-
curred upfront. The PPPM payments for LARC contracep-
tive payments reported in the current study are thus
substantially higher than if they were calculated for a lon-
ger follow-up (e.g., five years).
A previous actuarial analysis similar to the current study
was conducted on a commercially insured population [25].
Using the MedStat Marketscan Database for the year
2008, the authors found that costs PMPM for IUDs and
OCs represented 1.8% ($0.26/$14.64) and 11.7% ($1.72/
$14.64) of the cost of pregnancy, respectively. In the
current study, the payments PMPM of IUDs and OCs rep-
resented an even lower proportion of the payments of
pregnancy at 1.0% ($0.15/$14.81), and 1.5% ($0.23/$14.81),
respectively. The differences between the two studies
could be partly explained by the different study popula-
tions; the study by Fitch and colleagues was based on a
commercially insured population, while our study was
based on a Medicaid population. Nevertheless, both stud-
ies agree in the general finding that contraceptive coverage
represents a small proportion of pregnancy costs.
Moreover, the current findings can be used to highlight
potential cost savings of contraception, including LARC
methods, relative to costs incurred by unintended pregnan-
cies. As an example, contraceptive payments among IUD
users were estimated at $36.80 PPPM compared to $21.95
for unintended pregnancy PFCPM as estimated from the
actuarial analysis. Given that IUDs are expected to last sev-
eral years, these results suggest that cost savings associated
with the use of IUDs to prevent unintended pregnancy may
be achieved after only two years, as payments for IUDs
occur up front and were calculated based on up to 1 year
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PPPM). From a policy perspective, because we cannot dis-
tinguish between intended and unintended pregnancies, if
we assume that all women of childbearing age had used an
IUD and had no contraceptive failure, this would represent
cost savings of $3.55 PFCPM ($21.95-$18.40) in 2008, or
$1.37 PMPM on the whole Medicaid population. Similar
calculations for implant users and SARC users also result in
potential cost savings. Of course, in real life, not all women
would or should use an IUD or implant; many women
would prefer to choose a different type of contraception;
some women would not use any contraception at all, and
some women would want to become pregnant. Neverthe-
less, these potential savings from preventing unintended
pregnancies further support a need to provide women with
improved and affordable access to and choice between all
available contraceptive methods, including LARC methods.
A study of the 2002 National Survey of Family Growth
revealed that women aged 18 to 24 at risk of unintended
pregnancy were three times more likely to use a prescrip-
tion contraceptive when insured with Medicaid or with pri-
vate insurance than when uninsured [32]. Other studies
support the finding that fewer uninsured women at risk for
unintended pregnancies use prescribed contraceptives com-
pared to publicly or privately insured women [33,34]. Al-
though Medicaid federal guidelines require all states to
cover family planning services, they do not specify which
services must be provided. A nationwide state survey con-
ducted from Spring 2007 through Winter 2008 found that
32 states covered all types of prescription contraception as
a family planning service under Medicaid, 12 states some-
times considered all of them as family planning (4 did not
always consider OC under all circumstances), and 7 states
did not respond to the survey [35]. Among the states in-
cluded in the current study, Florida, Iowa, and Kansas in-
cluded all forms of contraceptives under the definition of
family planning services, Missouri excluded IUD removal,
whereas New Jersey did not respond to the survey. Thus,
inconsistent coverage of contraception under family plan-
ning services has likely resulted in decreased access and/or
utilization and thus more unintended pregnancies.
This study has several limitations. First, claims data may
have inaccuracies in the recorded information (e.g., diagno-
ses, payments). Second, there may be variations in the
coverage of contraceptive care among the five states in-
cluded in our Medicaid database; any such differences were
not taken into account in the analysis. Third, the study
evaluated only the direct medical payments of pregnancy.
Information to determine the indirect costs of pregnancy,
such as work productivity loss, was not available, and we
did not include the costs of newborn care. Fourth, the ob-
servational design was susceptible to various biases. For
example, contraceptives purchased over-the-counter were
not in the database, which may have resulted in anunderestimation of contraceptive payments. Finally, be-
cause exposure to contraceptives was not randomly
assigned across patients, there is the possibility of con-
founding by indication. Despite these limitations, the
current research has several advantages, including the im-
portance of relying on real-world data and a relatively large
sample size.
Conclusion
This large retrospective study of Medicaid female members
aged 14 to 49 years old showed that, over a follow-up period
of 12 months, healthcare payments for pregnancy are con-
siderably higher than payments for SARC and LARC users.
Healthcare payments for contraceptive methods represented
a small proportion of unintended pregnancy payments when
considered from the overall Medicaid population perspec-
tive over a full calendar year.
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